

India approves Israel-based neuro focused ultrasound platform

20 September 2021 | News

For treating Essential Tremor, Tremor-dominant Parkinson's Disease and Neuropathic Pain

Insightec[®], headquartered in Israel and the US, has announced that its incisionless neurosurgery platform, the Exablate[®] 4000, has received market approval by the Central Drugs Standard Control Organization (CDSCO), part of the Ministry of Health and Family Welfare of India.

The Exablate 4000 (Exablate Neuro) platform uses MR-guided focused ultrasound to precisely ablate a small target deep within the brain without incisions.

The approval will enable treatment of patients in India living with Essential Tremor, Tremor-dominant Parkinson's Disease and Neuropathic Pain.

Essential Tremor is a neurological condition that causes uncontrollable shaking in an estimated 41 million people worldwide.

"This technology offers appropriate patients immediate tremor control with a less invasive procedure that requires no incisions or anesthesia with minimal complications," said Prof. Paresh Doshi, Director of Neurosurgery at Jaslok Hospital and Research Centre and Group Advisor Functional Neurosurgery, Apollo Group of Hospitals, President of The Neuromodulation Society of India and Past President of the Indian Society for Stereotactic and Functional Neurosurgery. "Global clinical studies have demonstrated the procedure as approved is safe and helps patients to regain daily function."